Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE – Get a rating) CFO Tuesday sold 3,484 shares of the company in a trade dated Wednesday, October 12. The stock was sold at an average price of $38.22, for a total value of $133,158.48. Following the transaction, the CFO now directly owns 68,324 shares of the company, valued at approximately $2,611,343.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, accessible via this hyperlink.
Ultragenyx Pharmaceutical Stock Performance
RARE was down $1.75 during Friday’s trading, hitting $37.90. The company’s shares had a trading volume of 18,907 shares, compared to an average volume of 761,164. Ultragenyx Pharmaceutical Inc. has a 52-week low of $36.86 and a 52-week high of $89.56. The company’s fifty-day moving average price is $46.06 and its 200-day moving average price is $55.84. The company has a market capitalization of $2.65 billion, a price-earnings ratio of -5.42 and a beta of 1.24.
Ultragenyx Pharmaceutical (NASDAQ: RARE – Get a rating) last reported quarterly earnings data on Thursday, July 28. The biopharmaceutical company reported ($2.26) earnings per share for the quarter, missing analyst consensus estimates of ($1.72) by ($0.54). Ultragenyx Pharmaceutical had a negative net margin of 151.34% and a negative return on equity of 60.76%. The company posted revenue of $89.34 million in the quarter, compared to $87.33 million expected by analysts. During the same period of the previous year, the company posted ($1.45) EPS. Ultragenyx Pharmaceutical’s revenue for the quarter increased 2.7% compared to the same quarter last year. Stock analysts predict Ultragenyx Pharmaceutical Inc. to post earnings per share of -8.45 for the current year.
Institutional investors weigh in on Ultragenyx Pharmaceutical
Institutional investors have recently increased or reduced their stake in the company. Arizona State Retirement System increased its position in Ultragenyx Pharmaceutical shares by 0.9% during the first quarter. Arizona State Retirement System now owns 17,504 shares of the biopharmaceutical company valued at $1,271,000 after acquiring 159 additional shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in shares of Ultragenyx Pharmaceutical by 6.1% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,892 shares of the biopharmaceutical company valued at $283,000 after acquiring an additional 225 shares during the period. Lazard Asset Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 36.6% during the 1st quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company worth $64,000 after buying an additional 240 shares in the last quarter. Virtus ETF Advisers LLC increased its position in Ultragenyx Pharmaceutical shares by 7.6% during the second quarter. Virtus ETF Advisers LLC now owns 4,895 shares of the biopharmaceutical company worth $292,000 after buying 345 additional shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its position in Ultragenyx Pharmaceutical shares by 14.9% during the 1st quarter. Essex Investment Management Co. LLC now owns 2,682 shares of the biopharmaceutical company worth $195,000 after buying 348 additional shares in the last quarter. Hedge funds and other institutional investors own 88.27% of the company’s shares.
A Wall Street analyst gives his opinion
RARE has been the subject of several research reports. Stifel Nicolaus lowered his price target on Ultragenyx Pharmaceutical from $176.00 to $142.00 and set a “buy” rating on the stock in a Friday July 1 report. Barclays lowered its price target on Ultragenyx Pharmaceutical from $141.00 to $105.00 in a Friday July 29 report. StockNews.com began covering Ultragenyx Pharmaceutical in a report on Wednesday. They put a “sell” mark on the stock. Guggenheim upgraded Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and set a price target of $50.00 on the stock in a report on Thursday. Finally, Citigroup lowered its price target on Ultragenyx Pharmaceutical from $146.00 to $142.00 in a Wednesday, August 3 report. One research analyst rated the stock with a sell rating, two gave a hold rating and six issued a buy rating for the company’s stock. According to data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and an average price target of $106.92.
About Ultranyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally . Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi for the treatment of long chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Ultragenyx Pharmaceutical, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Ultragenyx Pharmaceutical didn’t make the list.
Although Ultragenyx Pharmaceutical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here